β Cell-specific deletion of guanylyl cyclase A, the receptor for atrial natriuretic peptide, accelerates obesity-induced glucose intolerance in mice

Sabine Tauscher¹, Hitoshi Nakagawa¹, Katharina Völker¹, Franziska Werner¹, Lisa Krebes¹, Tamara Potapenko¹, Sören Doose², Andreas L. Birkenfeld³, Hideo A. Baba⁴ and Michaela Kuhn¹*

Abstract

Background: The cardiac hormones atrial (ANP) and B-type natriuretic peptides (BNP) moderate arterial blood pressure and improve energy metabolism as well as insulin sensitivity via their shared cGMP-producing guanylyl cyclase-A (GC-A) receptor. Obesity is associated with impaired NP/GC-A/cGMP signaling, which possibly contributes to the development of type 2 diabetes and its cardiometabolic complications. In vitro, synthetic ANP, via GC-A, stimulates glucose-dependent insulin release from cultured pancreatic islets and β-cell proliferation. However, the relevance for systemic glucose homeostasis in vivo is not known. To dissect whether the endogenous cardiac hormones modulate the secretory function and/or proliferation of β-cells under (patho)physiological conditions in vivo, here we generated a novel genetic mouse model with selective disruption of the GC-A receptor in β-cells.

Methods: Mice with a floxed GC-A gene were bred to Rip-CreTG mice, thereby deleting GC-A selectively in β-cells (β GC-A KO). Weight gain, glucose tolerance, insulin sensitivity, and glucose-stimulated insulin secretion were monitored in normal diet (ND)- and high-fat diet (HFD)-fed mice. β-cell size and number were measured by immunofluorescence-based islet morphometry.

Results: In vitro, the insulinotropic and proliferative actions of ANP were abolished in islets isolated from β GC-A KO mice. Concordantly, in vivo, infusion of BNP mildly enhanced baseline plasma insulin levels and glucose-induced insulin secretion in control mice. This effect of exogenous BNP was abolished in β GC-A KO mice, corroborating the efficient inactivation of the GC-A receptor in β-cells. Despite this under physiological, ND conditions, fasted and fed insulin levels, glucose-induced insulin secretion, glucose tolerance and β-cell morphology were similar in β GC-A KO mice and control littermates. However, HFD-fed β GC-A KO animals had accelerated glucose intolerance and diminished adaptive β-cell proliferation.

Conclusions: Our studies of β GC-A KO mice demonstrate that the cardiac hormones ANP and BNP do not modulate β-cell’s growth and secretory functions under physiological, normal dietary conditions. However, endogenous NP/GC-A signaling improves the initial adaptive response of β-cells to HFD-induced obesity. Impaired β-cell NP/GC-A signaling in obese individuals might contribute to the development of type 2 diabetes.

Keywords: Natriuretic peptides, Guanylyl cyclase-A, Cyclic GMP, β-Cells, Insulin, Obesity
Background

To date, about 40–50% of the US and EU population is overweight and is presenting with a measurable insulin resistance. A significant part of this group will further proceed into development of type 2 diabetes mellitus with increased risk of cardiovascular complications including arterial hypertension and diabetic cardiomyopathy [1]. The heart is not only affected by metabolic disorders, but plays an active role in the defense against them [2–4]. Hence, the two cardiac hormones atrial (ANP) and B-type natriuretic peptides (BNP) not only moderate arterial blood pressure and intravascular volume but additionally improve systemic metabolism [reviewed in 5–7]. These pleiotropic endocrine actions are mediated by their shared transmembrane guanylyl cyclase (GC) receptor, GC-A (also named natriuretic peptide receptor A, NPR-A), which synthesizes cyclic GMP (cGMP) as second messenger [6]. The protective metabolic actions of the NP/GC-A signaling pathway involve lipolytic effects in adipocytes [7–9]; enhanced secretion of the adipokine adiponectin, an insulin-sensitizing hormone; energy expenditure in brown adipose tissue and “browning” of cells in white adipose depots [9]; as well as increased lipid oxidation in skeletal muscle (all reviewed in [5, 6]). Many clinical and experimental studies have demonstrated that obesity is associated with enhanced internalization and degradation of NPs through the NP clearance receptor (NPR-C) on adipocytes, lowering circulating NP levels and endocrine NP/GC-A signaling [10]. Evidence points towards a contribution of this “NP handicap” to the development of type 2 diabetes mellitus and cardiometabolic complications [4–6, 10, 11]. Vice versa genetic variants of the ANP or BNP genes (NPPA, NPPB) that result in an increase in circulating levels of NPs have been associated not only with lower blood pressure [12], but also with protection from the metabolic syndrome in the general population [13].

Studies with *exogenous*, synthetic NPs suggested that the protective metabolic inter-organ crosstalk effectuated by ANP and BNP might involve the endocrine pancreas. Hence, our previous results with cultured murine β-cells and isolated islets revealed that ANP, via GC-A/cGMP and cGMP-dependent protein kinase I, augments the effects of glucose on $K_{ATP}$ channel activity, $Ca^{2+}$ levels and insulin release [14]. Recently another in vitro study confirmed and extended our observations, showing that ANP enhances the insulinotrophic effects of the incretin hormone glucagon like peptide, GLP-1, in isolated murine islets [15]. Interestingly, it was also shown that long-term treatment of cultured pancreatic islets or immortalized β-cell lines with ANP enhances β-cell cyclin-D2 expression and proliferation [16]. The possible relevance for β-cell functions in vivo was addressed by pharmacological studies in human probands. Increased insulin levels and concomitant decreases of plasma glucose were observed during infusion of rather high doses of ANP in healthy subjects [17]. However, in other studies, infusion of more physiological, lower doses of ANP (leading to ~ 2.5-fold increases of plasma ANP levels) either had no effect on plasma insulin levels [18] or elicited only subtle and transient postprandial increases in plasma glucose and insulin [19].

Despite such controversial results, together these pharmacological studies raised the clinical concept that the natriuretic peptide handicap of obese individuals contributes not only to impaired insulin sensitivity but also to inappropriate β-cell insulin secretion [5, 15, 20]. However, all these previous in vivo/in vitro studies were performed with *exogenous* administered ANP or BNP, at concentrations which were ~ 100-fold higher as the circulating levels of the endogenous hormones. In fact, no single study addressed whether a NP-mediated axis between the heart and the endocrine pancreas participates in the regulation of β-cells functions under physiological or pathological conditions in vivo. To dissect whether the *endogenous* cardiac NPs regulate insulin secretion and/or the adaptative growth of β-cells, we used Cre/LoxP methodology to generate mice with constitutive, β-cell-specific knockout of the GC-A receptor for ANP/BNP (βGC-A KO).

Methods

**Generation of mice with β-cell-specific inactivation of GC-A**

All animal studies were approved by the Animal Care and Use Committee of Würzburg University and were in accordance with the Guide for the Care and Use of Laboratory Animals (NIH Publications No. 8023, revised 1978). To obtain mice with restricted ablation (KO) of GC-A in β-cells, mice with two floxed alleles of GC-A (GC-A/0/0 [21]) were intercrossed with RipCre<sup>+</sup> mice expressing Cre recombinase in β-cells under the control of the rat insulin 2 promoter. RipCre<sup>+</sup> mice were a gift from Pablo Herrera, Dept. of Genetic Medicine and Development, University of Geneva, Switzerland [22, 23]. Importantly, all metabolic parameters including β-cell function and morphology in this specific RipCre<sup>+</sup> line are unaltered [23].

Genotyings were performed by PCR of tail tip and tissue DNA using primers GC-A-1 (5′-TCTCTGCTCTCCGTTGACGTTCCC), GC-A-2 (5′-ATCAGAATACCCAGCCCGAGAAGACGC-GATGTTTGTAGTGCTTAC), which amplify a 186-bp fragment for the GC-A (Npr1) wild-type allele, a 343-bp fragment for the floxed allele, and a ~ 700 bp fragment for the knockout allele [21]. Presence of the Rip-Cre transgene was detected by PCR using primers Cre1
(5'-GCTGCCACGACCAAGTGACAGCAA) and Cre2 (5'-GTAGTTATTCGGATCATCAGCTACAC) (400-bp band). The hereby generated β GC-A KO mice (GC-Afl/fl; RipCreβ) and their littermate controls (GC-Aββ) were kept under a 12-h light/12-h dark cycle at constant temperature (23 °C) with unlimited access to food and water. All studies were performed with control and KO littermates of mixed background (C57BL/6J and 129SV).

**Metabolic studies**

For studies of diet-induced obesity a 60% high-fat diet (HFD, D12492, Research Diets) or the corresponding normal diet with 10% kcal from fat (ND, D12450B, Research Diets) were provided to 5 weeks old male β GC-A KO and control litters and maintained for 18 weeks [14]. At the defined time points, mice were euthanized under deep (3%) isoflurane anesthesia, and pancreata were processed for histology or dissection of islets.

All in vivo studies were performed between 0800 and 1000 h. Samples for determinations of blood glucose (Accu-check Mobile, Roche Diagnostics, Mannheim, Germany) and plasma insulin (Ultra Sensitive Mouse Insulin ELISA, Crystal Chem, Downers Grove, IL) were obtained from the tail vein [14]. For the oral (oGTT) or intraperitoneal (IP) glucose tolerance tests, mice were previously fasted for ~16 h. Mice received 2 g of glucose/intraperitoneal (IP) glucose tolerance tests, mice were obtained from the tail vein [14]. For the defined time points, mice were euthanized under deep (3%) isoflurane anesthesia, and pancreata were processed for histology or dissection of islets.

For studies of diet-induced obesity a 60% high-fat diet (HFD, D12492, Research Diets) or the corresponding normal diet with 10% kcal from fat (ND, D12450B, Research Diets) were provided to 5 weeks old male β GC-A KO and control litters and maintained for 18 weeks [14]. At the defined time points, mice were euthanized under deep (3%) isoflurane anesthesia, and pancreata were processed for histology or dissection of islets.

All in vivo studies were performed between 0800 and 1000 h. Samples for determinations of blood glucose (Accu-check Mobile, Roche Diagnostics, Mannheim, Germany) and plasma insulin (Ultra Sensitive Mouse Insulin ELISA, Crystal Chem, Downers Grove, IL) were obtained from the tail vein [14]. For the oral (oGTT) or intraperitoneal (IP) glucose tolerance tests, mice were previously fasted for ~16 h. Mice received 2 g of glucose/kg body weight (BW) in a volume of 10 μl/g BW and blood glucose concentrations were measured at 0, 15, 30, 60, 90 and 120 min [14]. In oGTTs, the samples obtained at 0, 15 and 30 min additionally served to determine basal and glucose-stimulated plasma insulin levels (GSIS). For the insulin tolerance test (ITT), fed mice were starved 4 h before the experiment. Insulin (1 IU/g BW; Actrapid Penfil Insulin human, Novo Nordisk, Bagsværd, Danemark) was injected intraperitoneally, and blood glucose concentrations were measured at 0, 15, 30 and 60 min. For glucose tolerance (GTT) and sensitivity (ITT), we measured the total area under the curve (AUC). The AUC was calculated from the baseline (0 min) and divided by the period of time [14].

**Administration of BNP via osmotic minipumps**

Mouse BNP (Bachem) was infused via subcutaneously implanted osmotic minipumps (model 1007D; Alzet Corporation) at a dose of 2 ng/h/g BW over 7 days [9]. The control group received pumps containing saline only.

**Immunohistochemistry and morphometrical analyses of pancreatic sections**

Pancreata were fixed with 4% paraformaldehyde, embedded in paraffin and cut in 8-μm sections. Insulin and glucagon stainings were performed with antibodies from Dako (Santa Clara, CA, USA; AB-1001362) and Sigma (Darmstadt, Germany; AB-259852), respectively [14]. Secondary antibodies (Jackson Immuno Research, West Grove, PA, USA) were Alexa Fluor 488 or CY3 coupled and were detected by immunofluorescence. DAPI was used to label nuclei (Dianova). Pictures of three whole sections of the pancreatic corpus per mouse were taken on an Olympus microscope. Fluorescent areas were measured with ImageJ software. The total islet area, area of insulin-positive β-cells and number of β-cells/islet were calculated [14]. The experimentators were blinded regarding genotype and treatment.

**Isolation and incubation of mouse pancreatic islets for determinations of intracellular cGMP, insulin secretion and cyclin-D2 mRNA expression**

Pancreatic islets were isolated by collagenase digestion and cultured overnight in RPMI 1640 medium (Gibco) containing 10% FCS [14]. Thereafter, islets were incubated at 37 °C in groups of 35 islets (for cGMP) or 10 islets (for insulin) in a buffer solution containing (in mM): 120 NaCl, 25 NaHCO3, 5 KCl, 2.5 CaCl2, 1 MgCl2, and 3 d-glucose (final pH 7.35). After 2 h, the solution was replaced by fresh solution containing 6 mM d-glucose with or without ANP and the islets were incubated for additional 15 min (for cGMP responses) or 60 min (for insulin secretion). For determination of ANP/cGMP effects, the islets were pretreated with the phosphodiesterase inhibitor 3-isobutyl-1-methylxanthine (0.5 μM IBMX (Sigma), 10 min). cGMP production was stopped by placing islets on ice; after centrifugation (100g, 5 min, 4 °C), the islets were lysed with ice-cold 70% (v/v) ethanol. cGMP was determined by radioimmunoassay (RIA) and normalized to sample protein contents (Bradford) [14, 21]. To evaluate the insulinotropic effects of ANP, insulin concentrations in supernatants were determined by ELISA [14]. To study the effects of ANP on mRNA expression levels of cyclin-D2, islets were serum-starved (1% FCS) for 24 h and thereafter ANP was added for another 24 h. The
supernatants were discarded and the islets (40 islets per condition) were lysed in TRIzol reagent (Invitrogen).

Gene expression studies
Total RNA was isolated from cultured or freshly picked mouse islets and cardiac left ventricles using TRIzol reagent (Life Technologies). After reverse transcription (Transcriptor First Strand cDNA Synthesis Kit, Roche), real-time RT-PCR was performed using a LightCycler Instrument (Roche) [24]. The following primers and probes from Roche were used: for GC-A, TGGAGACAC AGTCAACACAGC (forward primer); CCGAAGACAGTGGATCTCG (reverse primer) and probe #71 (cat. no. 04688945001); for BNP, AAG CTG CTG GAG CTG ATG AGA TCC TG (reverse primer) and probe #71 (cat. no. 04688945001). β2 Microglobulin (cat. no. 301208, FAM, Probe 117) or GAPDH (cat. no. 05046211001, Yellow) served as reference genes [24].

Plasma BNP levels
Plasma BNP levels were measured by enzyme immunoassay according to the manufacturer’s protocol (MyBioSource, Inc., San Diego, CA, USA). BNP was measured instead of ANP because circulating BNP levels showed better correlation with cardiac changes [3].

Statistical analysis
Data are presented as mean ± SEM (with the number of experiments described in the Legends to Figures). Student’s t test or two-way analysis of variance (ANOVA) followed by the Bonferroni post hoc test were used to examine differences between groups, as appropriate. P values < 0.05 were considered statistically significant.

Results
β-cell-specific GC-A deletion in GC-Afl/fl;Rip-Crelox mice
GC-Afl/fl mice with and without the Rip-Crelox were born in the expected Mendelian and sex ratios. PCR analysis of genomic DNA demonstrated that Cre-mediated complete recombination of the floxed GC-A gene only occurred in pancreatic islets (Fig. 1a). No deletion was detected in white adipose tissue, skeletal muscle, heart (Fig. 1a) or other tissues of the doubly transgenic (GC-Afl/fl;Rip-Crelox) mouse. To characterize the impact of this gene recombination event we studied GC-A mRNA expression and receptor function in islets isolated and cultured from both genotypes, ex vivo. Figure 1b shows that GC-A mRNA expression levels in islets prepared from GC-Afl/fl;Rip-Crelox mice were reduced by ~70% (as compared to islets from their GC-Afl/fl littermates).

As sensitive assay of ANP/GC-A signaling, we studied cGMP responses of isolated islets to ANP. As shown in Fig. 1c, ANP increased the cGMP contents of control islets (prepared from GC-Afl/fl mice) in a concentration-dependent manner. We then compared the responses of islets from GC-Afl/fl and GC-Afl/fl; Rip-Crelox littermates to a maximal ANP concentration (100 nM). As shown in Fig. 1d, the stimulatory effects of ANP on islets cGMP contents were markedly reduced in islets prepared from the double (GC-Afl/fl; Rip-Crelox) transgenic mice as compared to islets from GC-Afl/fl littermates. It is not surprising that the GC-A mRNA expression and cGMP activity were not fully abolished in the islets from the GC-Afl/fl; RipCrelox mice since the GC-A receptor is ablated in β-cells but preserved in other cell types of the islets. In particular, capillary endothelial cells have high GC-A expression levels [6, 24]. To overcome this limitation and dissect specific effects of ANP on β-cell function, we studied islet’s insulin release [14, 15]. As illustrated in Fig. 1e, ANP (10 nM during 1 h) enhanced glucose-dependent insulin secretion in islets isolated from control mice (GC-Afl/fl) but not in islets obtained from their GC-Afl/fl; RipCrelox littermates. Together, these experiments demonstrate the efficient inactivation of GC-A in β-cells from GC-Afl/fl; RipCrelox mice. Even more, whereas global GC-A KO mice are hypertensive [6], GC-Afl/fl; RipCrelox mice have unaltered arterial blood pressure (Fig. 1f), confirming that apart from β-cells, the effects of ANP/BNP on other target cells are preserved. Hence, we refer such mice as β-cell specific GC-A knockout (β GC-A KO) mice. Their GC-Afl/fl; flox/flox littermates without Cre were used as control mice in all subsequent experiments.

Disruption of ANP/GC-A signaling in pancreatic β-cells does not alter insulin-glucose homeostasis under physiological, normal dietary conditions
Since exogenous ANP enhanced glucose-dependent insulin secretion from control but not from β GC-A KO islets in vitro, we expected that β GC-A KO mice (in vivo) would display diminished insulin levels and impaired glucose tolerance. However, fasting or random fed plasma insulin concentrations and oral glucose-stimulated insulin levels (GSIS) were not different between genotypes (Fig. 2a, b). Consistently, the oGTT and ipGTT revealed that glucose handling was similar in β GC-A KO mice as compared to their control littermates (Fig. 2c, d). Together these studies demonstrate that the endogenous cardiac NP/GC-A signaling pathway does not critically modulate resting or glucose-stimulated secretory functions of β-cells under physiological, normal dietary conditions in vivo.
Fig. 1 Deletion of GC-A in β-cells from GC-A\textsuperscript{fl/fl}, Rip-Cre\textsuperscript{Tg} (β GC-A KO) mice. 

a PCR analysis. Genomic DNA from different tissues was assayed for the appearance of the ~700-bp amplicon which results from complete recombination of the floxed GC-A gene segment. Genomic DNA was from white adipose tissue (WAT), skeletal muscle (Sk M), isolated pancreatic islets and hearts.

b Quantitative RT-PCR analysis. GC-A mRNA expression levels in pancreatic islets from control and β GC-A KO mice. Values are the ratio of GC-A mRNA level relative to β2 microglobulin, expressed as x-fold vs control islets (20 samples per genotype).

c Cyclic GMP determinations. Concentration-dependent effects of ANP on intracellular cGMP contents of pancreatic islets prepared and cultured from control mice (15 min incubation in the presence of the phosphodiesterase inhibitor IBMX; n = 4 per condition).

d Comparison of the cGMP responses of β GC-A KO and control islets to 100 nM ANP (15 min incubation in the presence of IBMX; n = 4 per genotype and condition).

e Insulin release. Effects of ANP on glucose-dependent insulin secretion by pancreatic islets prepared from β GC-A KO and control littermates (1 h incubation; n = 4).

f Systolic, mean and diastolic arterial blood pressure levels of β GC-A KO and control littermates (n = 16 per genotype). *P < 0.05 vs vehicle; #P < 0.05 vs controls.
Increasing circulating BNP levels by *exogenous* BNP administration enhances glucose-stimulated insulin secretion via the GC-A receptor on β-cells

Infusion of ANP increases circulating insulin in human probands [17]. To dissect whether this effect is mediated by the GC-A receptor on β-cells, we compared the actions of infused BNP on plasma insulin levels in control and β GC-A KO mice. We used BNP instead of ANP because it has almost the same affinity for GC-A as ANP, but higher stability and plasma half life [6, 9]. Osmotic minipumps filled with vehicle or synthetic BNP (to deliver 2 ng BNP/h/g BW [9]) were implanted subcutaneously for 7 days. It was previously shown that this protocol results in a 2-fold increase of baseline BNP plasma levels [9]. In the control mice, fasted (basal) and oral glucose-stimulated plasma insulin levels were mildly but significantly enhanced by BNP (Fig. 3a). This was accompanied by a mild decrease in fasted plasma glucose levels and slightly improved oral glucose tolerance (Fig. 3a, bottom). Notably, such effects of infused, *exogenous* BNP on plasma insulin levels and oral glucose tolerance were fully abolished in the β GC-A KO mice (Fig. 3b). These results extend the observations in isolated islets showing that elevated NP levels can enhance glucose-dependent insulin release. They demonstrate that this effect is mediated by GC-A signaling in β-cells.

HFD-fed β GC-A KO mice exhibited accelerated glucose intolerance

To study whether *endogenous* NP/GC-A signaling improves β-cell functions under pathological conditions such as obesity-induced insulin resistance, control and β GC-A KO mice were fed a HFD starting at 5 weeks of age. Compared to control littermates, β GC-A KO mice had similar body weight gain (Fig. 4a) and food consumption (not shown). After 15 weeks of HFD the mean BWs were 33 ± 1.8 g (control mice) and 32.6 ± 1.8 g (KO mice), representing a weight gain of ~23% as compared to mice under ND. In both genotypes, obesity was associated with mild but significant increases of systolic and
diastolic blood pressure levels (Fig. 4b). Notably cardiac left ventricular BNP mRNA expression levels were increased under HFD (Fig. 4c). Despite, plasma BNP levels were mildly but significantly decreased under HFD (Fig. 4d). Although the circulating BNP levels were similar in both genotypes (Fig. 4d), the cGMP contents of islets freshly prepared from the β GC-A KO mice were markedly diminished as compared to controls (Fig. 4e). This corroborates abolished GC-A signaling in β-cells.

After 4 weeks on HFD, fasted blood glucose levels and glucose tolerance (oGTT) were still unaltered (not shown). Notably, after 8 weeks on HFD, only the β GC-A KO mice had significantly enhanced fasted glucose levels (Fig. 5a). The oGTT revealed that glucose tolerance was only mildly changed in the control mice but markedly impaired in their KO littermates on HFD (Fig. 5b). Concordantly, the AUC for the oGTT was significantly greater for the β GC-A KO mice compared to control mice on HFD or to KO mice on ND (Fig. 5c). These genotype-dependent differences vanished after 12 and 18 weeks on HFD, with both genotypes now showing similar pathological oGTTs (Fig. 5c). In agreement with a selective abrogation of NP/GC-A signaling in β-cells, the ITT showed similar insulin sensitivities in control and β GC-A KO mice on HFD (Fig. 5d). Figure 5e illustrates that the fasted (basal) and glucose-stimulated plasma insulin levels (GSI) were markedly higher under HFD (right panel) as compared to ND (left panel), corroborating HFD-induced insulin resistance. However, surprisingly we did not observe genotype-dependent differences.

**The NP/GC-A system improves adaptive β-cell growth in diet-induced obesity**

Previous studies showed that ANP enhances β-cell cyclin-D2 expression and proliferation of cultured β-cells in vitro [16]. Accordingly, in the present studies ANP (1–100 nM, 24 h) evoked significant and concentration-dependent increases of cyclin-D2 mRNA expression (as marker for β-cell proliferation) in islets isolated from control mice (Fig. 6a). We then compared the responses of islets from control and β GC-A KO littermates to
the threshold ANP concentration (1 nM). As shown in Fig. 6b, the stimulatory effect of ANP on cyclin-D2 expression was abolished in islets prepared from the KO mice and is therefore mediated by the GC-A receptor.

To follow the hypothesis that the NP/GC-A system contributes to the initial adaptative increase in β-cell mass which occurs in clinical and experimental type 2 diabetes [25, 26], we performed studies of islets morphology and gene expression in control and β GC-A KO mice after 8 weeks of HFD or the corresponding ND. Morphometrical analyses of pancreatic sections stained for insulin, glucagon and DAPI demonstrated that in control mice a HFD provoked significant increases of islet areas, i.e. of the area occupied by β-cells, which was due to an increase in their numbers (Fig. 6c). Notably, this adaptative β-cell proliferation was attenuated in β GC-A KO littermates on a HFD (Fig. 6c). Concordantly, quantitative RT-PCR revealed that the expression of cyclin-D2 was enhanced in islets from HFD-fed control mice, although the difference to ND was not statistically significant (P = 0.09; Fig. 6d). Notably, cyclin-D2 levels in islets prepared from HFD-fed β GC-A KO mice were clearly and significantly lower in comparison to islets from HFD-fed control littermates (Fig. 6d). Together these observations indicate that NPs support adaptative β-cell proliferation during early stages of increased insulin demand, here provoked by HFD as experimental model of type 2 diabetes.

**Discussion**

Cardiac natriuretic peptides are well known for their cardiovascular functions [6]. In the past years, many published experimental and clinical investigations demonstrated that NPs, via the GC-A receptor, improve insulin sensitivity in the adipose tissue, skeletal muscle, and liver, thereby involving the heart in energy
Fig. 5  HFD-fed β GC-A KO mice exhibit accelerated glucose intolerance. Fasting blood glucose concentrations (a) and blood glucose concentrations during oral glucose tolerance test (oGTT, b) were determined in 16-h-fasted β GC-A KO and control littermates after 8 weeks of ND or HFD (n = 13 mice per genotype and condition). c Area under the curve (AUC) during oral glucose tolerance tests (oGTT) performed in 16-h-fasted β GC-A KO and control littermates after 8 weeks (n = 13), 12 weeks (n = 6–8) or 18 weeks (n = 6–8) of ND or HFD. d Blood glucose concentration and area under the curve (AUC) during insulin tolerance test (ITT) performed in 4-h-fasted β GC-A KO and control mice after 8 weeks of HFD (n = 10 per genotype). e Fasting (basal) plasma insulin levels and glucose-stimulated insulin secretion (GSIS) were determined in 16-h-fasted β GC-A KO and control littermates on ND (left panel) or HFD (right panel) (n = 10 per genotype). *P < 0.05 vs ND or basal; **P < 0.05 vs control mice
metabolism [2, 5–9]. Recent studies of isolated cultured mouse pancreatic islets indicated that NP/GC-A signaling may additionally enhance stimulus-secretion coupling of pancreatic β-cells: directly, by augmenting glucose-dependent insulin release; and indirectly, by potentiating the effect of the incretin hormone GLP-1.
[14, 15]. Such in vitro studies raised the concept that NPs connect the heart with the endocrine pancreas to enhance physiological postprandial insulin secretion [15, 20, 27]. However, they harbor the important limitation that the synthetic NPs were tested at concentrations which were >100 to 1000-folds higher (10 nM) as compared to the physiological range of resting circulating ANP or BNP levels in healthy probands (10–50 pM [28–30]) or mice (100–200 pM [31]; ~300 pM BNP in the present study). Even after a meal or a 75-g OGTT, the plasma concentrations of ANP in humans only increase modestly by ~10% [28]. Larger, 2 to 10-fold increases of plasma ANP/BNP levels are induced by exercise [29] or exposure to cold temperatures [9]. Because the concept of an NP-mediated endocrine connection between the heart and the pancreas would have important (patho)physiological and clinical implications, the present in vivo studies addressed three questions: (1) does NP/GC-A signaling in β-cells modulate baseline or acute glucose-stimulated insulin secretion under resting, physiological conditions in vivo?; (2) does a subtle, more physiological increase of plasma NP levels, as occurs for instance in exercise or coldness [9, 29], improve glucose-stimulated insulin release?; and (3) does impaired NP/GC-A signaling in β-cells enhance their vulnerability to diabetogenic stimuli, such as HFD? To answer these questions we performed metabolic studies (in vivo) in mice with selective inactivation of the GC-A receptor in β-cells.

Does NP/GC-A signaling in β-cells modulate stimulus-secretion coupling under physiological conditions?

As illustrated, ANP enhanced glucose-dependent insulin release from control but not from β GC-A KO islets, which is consistent with other published in vitro studies [14, 15]. However, under baseline, physiological conditions glucose-induced insulin secretion (GSIS) and oral or IP glucose tolerance were not different between β GC-A KO and control littermates (in vivo). The fact that oral and IP glucose had similar effects on plasma glucose and insulin levels in both genotypes largely excludes the possibility that the endogenous cardiac NPs, at physiological plasma levels, augment stimulus-secretion coupling or the modulatory effects of incretins such as GLP-1 in vivo, for instance after a meal. Also, β-cell size and numbers were not different between the two genotypes. Hence, although β-cells express GC-A receptors [14–16; present study], NP/GC-A signaling is dispensable for baseline or postprandial insulin release under resting, physiological conditions.

Does a mild chronic increase of plasma NP levels improve β-cell insulin secretion?

In our pharmacological studies, a low dose of BNP infused during 7 days, resulting in a ~2-fold increase of plasma BNP levels [9], mildly but significantly increased baseline and glucose-stimulated insulin levels and improved oral glucose tolerance in control mice. These effects of exogenous BNP were abolished in β GC-A KO littermates demonstrating that they were mediated by β-cell GC-A signaling. Notably human studies have shown an association of a single nucleotide polymorphism rs5068 on the natriuretic peptide precursor A (NPPA) locus gene with higher levels of circulating ANP and lower likelihood of incident diabetes [13]. Our data indicate that this inverse correlation might be partly due to protective effects of sustained elevations of endogenous NP on β-cell functions.

Does impaired NP/GC-A signaling in β-cells enhance their vulnerability to diabetogenic stimuli, such as HFD?

In general, apart from their diverse acute cardiovascular and metabolic effects, NPs exert chronic effects on cell growth and proliferation. They inhibit cardiac myocyte hypertrophy and fibroblast proliferation, but stimulate the proliferation of vascular endothelial cells or renal podocytes (all reviewed in [6]). These studies also demonstrated that such effects of NPs are not relevant under baseline, physiological conditions but markedly impact cardiac remodeling, angiogenesis or podocyte regeneration under disease conditions [32–34]. As already mentioned, it was also shown that ANP can stimulate the proliferation of cultured rat pancreatic islets β-cells and insulinoma cells (INS-1E) via GC-A/cGMP-dependent activation of phosphatidylinositol 3′-kinase and Akt/Foxo1a/cyclin-D2 signaling [16]. In line with these observations, ANP enhanced cyclin-D2 mRNA expression levels in islets isolated from control but not from β GC-A KO mice (present studies). It is well known that under physiological conditions, β-cells barely proliferate. However, in initial stages of clinical or experimental prediabetes type 2, e.g. in obesity, the endocrine pancreas compensates for insulin resistance by increasing β-cell mass and insulin secretion [25, 26, 35]. Later on β-cell failure caused by a loss of cells and reduced insulin secretion from remaining individual β-cells leads to overt diabetes [35]. To study whether in this situation the endogenous NP/GC-A system modulates β-cell proliferation and function, control and β GC-A KO littermates were fed a HFD, a condition known to provoke obesity, arterial hypertension, insulin resistance and enhanced β-cell proliferation in mice [8, 35, 36]. Control and β GC-A KO mice showed similar weight gain,
insulin sensitivity (ITT) and arterial hypertension under HFD. Cardiac BNP mRNA expression levels were doubled, possibly in response to increased cardiac afterload [3]. However, circulating BNP levels were lower under HFD as compared to ND, which is consistent with many published clinical and experimental studies showing that obese and type-2 diabetics display reduced circulating NP levels [5]. This has been linked to enhanced expression of the natriuretic peptide clearance receptor, NPR-C, in adipocytes [5, 9, 37]. Importantly, while these systemic effects of HFD (on blood pressure and BNP expression and circulation) were similar in control and β GC-A KO mice, islets freshly prepared from the later mice had markedly reduced cGMP contents, which is consistent with local ablation of the GC-A receptor.

In control mice, the size of the endocrine islets, the total number of β-cells per islet as well as islet cyclin-D2 expression levels were already increased after 2 months of high-fat feeding. Notably, these adaptive morphological and molecular changes were absent in β GC-A KO mice. Accordingly, these mice showed accelerated glucose intolerance already at 2 months of HFD (shown by oGTT), although plasma insulin levels apparently were unaltered. The mismatch between the increased glucose excursion during the oGTT in β GC-A KO mice and similar glucose-induced insulin levels (GSIS) in comparison to control littermates suggests that islet β-cells lacking GC-A are not able to compensate sufficiently for an increased glucose excursion during the development of an increased insulin demand (here provoked by HFD). Further studies are needed to clarify the exact mechanism.

The molecular pathways that are activated and drive the increases in β-cell mass in obesity and insulin resistance have yet to be fully elucidated [38]. High glucose levels and incretine hormones such as GLP-1 might be involved [38, 39]. Our data suggest that cardiac NPs, via GC-A/cGMP signaling, support these pathways and thereby the adaptive proliferation of β-cells during early stages of obesity-linked insulin resistance and metabolic syndrome.

Limitations of the study
Our study harbors three limitations:

• We could not corroborate β-cell GC-A deletion by immunohistochemistry. We have tested commercially available and own anti-GC-A antibodies and observed unspecific cross-reactions of all antibodies. However, the following functional experiments demonstrated the efficient deletion of GC-A in β-cells from the GC-Aβ/β; RipCreβ litter mice: the stimulatory effects of synthetic NPs on glucose-dependent insulin release (in vitro/in vivo) and islet cyclin-D2 expression (in vitro) were fully abolished. Corroborating these results, a recently published in vitro study showed that synthetic ANP modulates KATP channel activity and Ca2+ levels of β-cells isolated from the here generated GC-Aβ/β mice but not from their GC-Aβ/β; RipCreβ littermates [15]. In addition, we have demonstrated the efficient Cre/lox-mediated cell-restricted deletion of GC-A in many previous studies with these GC-Aβ/β mice [21, 32–34].

• Transcription from the Rip (insulin 2) promoter starts during pancreas development [23]. We cannot exclude adaptive developmental changes in the double transgenic (GC-Aβ/β; RipCreβ) mice, but the absence of changes in β-cell and islet morphology and function under baseline (normal dietary) conditions throughout age argues against developmental changes.

• Throughout all experiments, we compared GC-Aβ/β (controls) and their β GC-A KO littermates. Rip-Cre mice were not included as a control group, since (i) they cannot be studied as littermates; (ii) we did not observe genotype-dependent differences in oGTT, insulin release and sensitivity or body weights at most time points; and (iii) previous studies demonstrated that metabolic parameters and β-cell function and morphology in this specific Rip-Cre line are undistinguishable from control mice [23].

Conclusions
Our comparative investigations of β GC-A KO and control littermates reveal that the cardiac hormones ANP and BNP do not modulate stimulus-secretion coupling of pancreatic β-cells under resting, physiological conditions. However, endogenous NPs contribute to the control of glucose homeostasis under conditions of pathological diet-induced obesity by improving β-cell proliferation and function in early stages of enhanced insulin demand. Large prospective studies in nondiabetic individuals showed that low initial plasma levels of ANP or BNP predict development of future diabetes and glucose progression over time, suggesting a causal role of chronic NP deficiency in diabetes development [11, 37, 40]. Conversely, higher NT-proBNP is associated with decreased risk of incident diabetes even after adjustment for traditional risk factors [41]. Our experimental observations add an important novel piece of information, indicating that deficient NP/GC-A signaling in β-cells impairs adaptive β-cell proliferation and glucose tolerance during developing obesity, which could be involved in the pathogenesis of type 2 diabetes in its early stages.
Abbreviations
ANP: atrial natriuretic peptide; BNP: B-type natriuretic peptide; GC-A: guanylyl cyclase A (also named NPR-A: natriuretic peptide receptor type A); β-GC-A KO: mice with β-cell restricted deletion of the GC-A receptor; qRT-PCR: quantitative real-time PCR; TEF: tissue expansion factor; GSD: glucose stimulated insulin secretion.

Authors’ contributions
ST, HN and KF performed the metabolic studies, studies of isolated islets and histological examinations. FW designed and performed the qRT-PCR analyses. UK and TP took care of mouse breedings, genotypings and cGMP determinations. SD and HAB contributed to the histological and morphometrical studies. ALB provided critical advice to the metabolic studies and valuable discussions. MK designed and coordinated the studies, analyzed the data and wrote the manuscript. All authors read and approved the final manuscript.

Author details
1 Institute of Physiology, University of Würzburg, Röntgenring 9, 97070 Würzburg, Germany. 2 Department of Biotechnology and Biophysics, University of Würzburg, Am Hubland, 97074 Würzburg, Germany. 3 Paul Langerhans Institute Dresden of the Helmholtz Center Munich at University Hospital and Faculty of Medicine, TU Dresden, Fetscherstraße 74, 01307 Dresden, Germany. 4 Institute of Pathology and Neuropathology, University Hospital Essen, Hufelandstraße 55, 45147 Essen, Germany.

Acknowledgements
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Availability of data and materials
All data generated or analysed during this study are included in this article.

Consent for publication
Not applicable.

Ethics approval and consent to participate
A statement on ethics approval for animal studies has been included.

Availability of data and materials
All data generated or analysed during this study are included in this article.

Funding
This work was supported by the Deutsche Forschungsgemeinschaft (DFG KU 1037/5-1 and TR166) and by the German Ministry of Research and Education.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 6 March 2018 Accepted: 11 July 2018
Published online: 17 July 2018

References
1. Jia G, Whaley-Connell A, Sowers JR. Diabetic cardiomyopathy: a hyperglycaemia- and insulin-resistance-induced heart disease. Diabetologia. 2018;61(1):21–8. https://doi.org/10.1007/s00125-017-4390-4.
2. Pang A, Hu Y, Zhou P, Long G, Tian X, Men L, Shen Y, Liu Y, Cui Y. Corin is down-regulated and exerts cardioprotective action via activating pro-atrial natriuretic peptide pathway in diabetic cardiomyopathy. Cardiovasc Diabetol. 2015;14:134–40. https://doi.org/10.1186/s12933-015-0298-9.
3. Nunes S, Soares E, Fernandes J, Viana S, Carvalho E, Pereira FC, Reis F. Early cardiac changes in a rat model of prediabetes: brain natriuretic peptide overexpression seems to be the best marker. Cardiovasc Diabetol. 2013;12:44–52. https://doi.org/10.1186/1475-2840-12-44.
4. Baldassarre S, Fragapane S, Panerai A, Fedele D, Pinachi S, Lucchini M, Vitale AR, Mengozzi G, Gruden G, Bruno G. NProBNP in insulin-resistance mediated conditions: overweight/obesity, metabolic syndrome and diabetes.

The population-based Casale Monferrato Study. Cardiovasc Diabetol. 2017;16:119. https://doi.org/10.1186/s12933-017-0601-z.
5. Ramos HR, Birkenfeld AL, de Bold AJ. INTERACTING DISCIPLINES: cardiac natriuretic peptides and obesity: perspectives from an endocrinologist and a cardiologist. Endocr Rev. 2015;45(3):R25–36. https://doi.org/10.1210/er.2015-00018.
6. Kuhn M. Molecular physiology of membrane guanylyl cyclase receptors. Physiol Rev. 2016;96(2):751–804. https://doi.org/10.1152/physrev.00022.2015.
7. Moro C, Crampes F, Sengenes C, De Giuli S, Galletti T, Thalamas C, Lafontan M, Berlan M. Atrial natriuretic peptide contributes to physiolog-ical control of lipid mobilization in humans. FASEB J. 2004(17):908–10.
8. Wu W, Shi F, Liu D, Ceddia RP, Gaffin R, Wei W, et al. Enhancing natriuretic peptide signaling in adipose tissue, but not in muscle, protects against diet-induced obesity and insulin resistance. Sci Signal. 2017;10(489).https://doi.org/10.1126/scisignal.aag6870.
9. Bordicchia M, Liu D, Amri EZ, Alhau G, Desli-Fulgheri P, Zhang C, et al. Cardiac natriuretic peptides act via cGMP MAPK to induce the brown fat thermogenic program in mouse and human adipocytes. J Clin Invest. 2012;122(3):1022–36. https://doi.org/10.1172/JCI59701.
10. Nannipieri M, Seguini G, Catalano C, Prontera T, Baldi S, Ferrannini E. Defective regulation and action of ANP in type 2 diabetes. Horm Metab Res. 2002;34(5):265–70. https://doi.org/10.1007/s0002-002-3141-4.
11. Magnusson M, Juij J, Hedblad B, Engstrom G, Persson M, Strick J, et al. Low plasma level of atrial natriuretic peptide predicts development of diabetes: the prospective Malmo Diet and Cancer study. J Clin Endocrinol Metab. 2013;97(2):638–45. https://doi.org/10.1210/jc.2012-2425.
12. Newton-Cheah C, Larson MG, Levy D, Bloch KD, Surti A, et al. Association of common variants in NPPA and NPPB with circulating natriuretic peptides and blood pressure. Nat Genet. 2009;41(3):348–53. https://doi.org/10.1038/ng.328.
13. Canonne V, Boerigter G, Catalotti A, Costello-Boerrigter LC, Olson TM, McKie PM, et al. A genetic variant of the atrial natriuretic peptide gene is associated with cardiometabolic protection in the general community. J Am Coll Cardiol. 2011;58(7):629–36. https://doi.org/10.1016/j.jacc.2011.05.011.
14. Porego AB, Soriano S, Tuduri E, Maroquel L, Téllez N, Gassner B, et al. The atrial natriuretic peptide (ANP) and guanylyl cyclase-A system modulates pancreatic β-cell function. Endocrinology. 2010;151(8):3665–74. https://doi.org/10.1210/en.2010-0119.
15. Undank S, Kaefer K, Systimic J, Duffer M, Krippert-Drews P, Drews G. Atrial natriuretic peptide affects stimulus-secretion coupling of pancreatic β-cells. Diabetes. 201766(11):2840–8. https://doi.org/10.2337/db17-0392.
16. You H, Laychock SG. Atrial natriuretic peptide promotes pancreatic islet beta-cell growth and Akt/Foxo1a/cyclin D2 signaling. Endocrinology. 2009;150(2):5455–65. https://doi.org/10.1210/en.2009-0468.
17. Uehlinger DE, Weidmann P, Gnaedinger MP, Hasler L, Bachmann C, Shaw S, et al. Increase in circulating insulin induced by atrial natriuretic peptide (ANP) in normal humans. J Cardiovasc Pharmacol. 1986;8(5):1122–9. https://doi.org/10.1210/jcem-62-5-1027.
18. Ferrari P, Shaw S, Riesen W, Weidmann P. Plasma insulin during physiological and pathophysiolog-ical changes in atrial natriuretic factor. Eur J Clin Pharmacol. 1992;42(4):453–5.
19. Birkenfeld AL, Budzirek P, Buschmann M, Moro C, Adams F, Franke G, et al. Atrial natriuretic peptide induces postprandial lipid oxidation in humans. Diabetes. 2006;55(12):3199–204. https://doi.org/10.2337/db06-0649.
20. Gruden G, Landi A, Bruno G. Natriuretic peptides, heart, and adipose tissue: new findings and future developments for diabetes research. Diab Care. 2014;37(11):2899–908. https://doi.org/10.2337/dc14-0669.Review.
21. Holtwick R, Gortthaid M, Skyblain B, Steinmetz M, Potthast R, Zeitsch B, et al. Smooth muscle-selective deletion of guanylyl cyclase-A prevents the acute but not chronic effects of ANP on blood pressure. Proc Natl Acad Sci USA. 2002;99(10):7142–7. https://doi.org/10.1073/pnas.10265 049.
22. Herrera PL. Adult insulin- and glucagon-producing cells differentiate from two independent cell lineages. Development. 2000;127(11):2317–22.
23. Genina E, Tronche F, Herrera P, Duchen E, Tales W, Czernicki P, et al. Dissecting the role of glucocorticoids on pancreas development. Diabetes. 2004;53(9):2322–9. https://doi.org/10.2337/diabetes.53.9.2322.
24. Chen W, Spitzl A, Mathes D, Nikolaev VO, Werner F, Weirather J, et al. Endothelial actions of ANP enhance myocardial inflammatory infiltration in the early phase after acute infarction. Circ Res. 2016;119(2):237–48. https://doi.org/10.1161/CIRCRESAHA.115.307196.

25. Lingorh MK, Buettner R, Rhodes CJ. Pancreatic beta-cell growth and survival—a role in obesity-linked type 2 diabetes? Trends Mol Med. 2002;8(8):375–84. https://doi.org/10.1016/S1471-4914(02)02377-8.

26. Mezza T, Muscogiuri G, Sorice GP, Clemente G, Hu J, Pontecorvi A, et al. Insulin resistance alters islet morphology in nonobese humans. Diabetes. 2014;63(3):994–1007. https://doi.org/10.2337/db13-1013.

27. Verboven K, Hansen D, Jocken JEW, Blaak EE. Natriuretic peptides in the control of lipid metabolism and insulin sensitivity. Obes Rev. 2017;18(11):1243–59. https://doi.org/10.1111/obr.12598.

28. Sonne DP, Terzic D, Knop FK, Goetze JP. Postprandial plasma concentrations of ProANP in patients with type 2 diabetes and healthy controls. Clin Chem. 2017;63(5):1040–1. https://doi.org/10.1373/clinchem.2016.268060.

29. Moro C, Pillard F, de Glisezinski I, Klimcakova E, Campes F, Thalamas C, et al. Exercise-induced lipid mobilization in subcutaneous adipose tissue is mainly related to natriuretic peptides in overweight men. Am J Physiol. 2008;295(2):E505–13. https://doi.org/10.1152/ajpendo.90227.2008.

30. Haufe S, Kaminski J, Utz W, Haas V, Mahler A, Daniels MA, et al. Differential response of the natriuretic peptide system to weight loss and exercise in overweight or obese patients. J Hypertens. 2015;33(9):1458–64. https://doi.org/10.1097/JHJ.0000000000000573.

31. Lopez MJ, Garbers DL, Kuhn M. The guanylyl cyclase-deficient mouse defines differential pathways of natriuretic peptide signaling. J Biol Chem. 1997;272(37):23064–8. https://doi.org/10.1074/jbc.272.37.23064.

32. Holtwick R, van Eickels M, Skryabin BV, Baba HA, Bubikat A, Begrow F, et al. Pressure-independent cardiac hypertrophy in mice with cardiomyocyte-restricted inactivation of the atrial natriuretic peptide receptor guanylyl cyclase-A. J Clin Invest. 2003;111(9):1399–407. https://doi.org/10.1172/JCI17061.

33. Staffel J, Vellatella D, Federlein A, Ehm K, Vollmann R, Fuchs AM, et al. Natriuretic peptide receptor guanylyl cyclase-A in podocytes is renoprotective but dispensable for physiologic renal function. J Am Soc Nephrol. 2017;28(1):260–7. https://doi.org/10.1681/ASN.2015070731.

34. Kuhn M, Wöller K, Schwarz K, Carbajo-Lozoya I, Flogel U, Jacoby C, et al. The natriuretic peptide/guanylyl cyclase-A system functions as a stress-responsive regulator of angiogenesis in mice. J Clin Investig. 2009;119(7):29–39. https://doi.org/10.1172/JCI37430.

35. Ahrén J, Ahrén B, Wierup N. Increased β-cell volume in mice fed a high-fat diet: a dynamic study over 12 months. Islets. 2010;2(6):353–6.

36. Chaar LJ, Coelho A, Silva NM, Festuccia WL, Antune VR. High-fat diet-induced hypertension and autonomic imbalance are associated with an upregulation of CART in the dorsomedial hypothalamus of mice. Physiol Rep. 2016;4(11):pii: e12811. https://doi.org/10.14814/phy2.12811.

37. Gentili A, Frangione MR, Albini E, Vaccia C, Ricci MA, De Vuono S, et al. Modulation of natriuretic peptide receptors in human adipose tissue: molecular mechanisms behind the “natriuretic handicap” in morbidly obese patients. Transl Res. 2017;186:52–61. https://doi.org/10.1016/j.trsl.2017.06.001.

38. Zhou Q, Melton DA. Pancreas regeneration. Nature. 2018;557(7705):351–8. https://doi.org/10.1038/s41586-018-0088-0.

39. Ma X, Guan Y, Hua X. Glucagon-like peptide 1-potentiated insulin secretion and proliferation of pancreatic β-cells. J Diabetes. 2014;6:394–402. https://doi.org/10.1111/1753-0407.12161.

40. Jujj A, Nilsson PM, Engström G, Hedblad B, Melander O, Magnusson M. Atrial natriuretic peptide and type 2 diabetes development: biomarker and genotype association study. PLoS ONE. 2014;9(2):e89201. https://doi.org/10.1371/journal.pone.0089201.

41. Brutsaert FF, Biggs ML, Delaney JA, Djoussé L, Gottdiener JS, lv JH, et al. Longitudinal assessment of N-terminal pro-B-type natriuretic peptide and risk of diabetes in older adults: the cardiovascular health study. Metabolism. 2016;65(10):1489–97. https://doi.org/10.1016/j.metabol.2016.06.002.